571 results on '"van Beers, Eduard J."'
Search Results
2. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency
3. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
4. Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
5. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
6. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme
7. Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency
8. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
9. Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency
10. Osmotic gradient ektacytometry - a novel diagnostic approach for neuroacanthocytosis syndromes.
11. Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry.
12. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease
13. A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease
14. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease
15. Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease.
16. Red Blood Cell Biochemistry and Physiology
17. Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease.
18. A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.
19. A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia
20. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
21. Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]
22. Red Blood Cell Biochemistry and Physiology
23. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
24. Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet
25. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry:rationale and study design
26. A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia
27. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias:Shedding new light on an old enzyme
28. A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia
29. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study
30. Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme
31. The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
32. Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency
33. Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet
34. Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis: A case series and literature review
35. A novel missense variant in $ATP11C$ is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia
36. Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency
37. Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency
38. Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients with Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response
39. Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
40. Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry
41. Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry
42. An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease
43. Movement Behavior in Adults with Sickle Cell Disease Compared to Healthy Adults: Preliminary Results
44. The Launch of Two Sub-Studies of the Peak Registry, a Global, Longitudinal Study of Pyruvate Kinase Deficiency
45. Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency
46. Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
47. Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
48. A reply to Moris et al.
49. Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis: A case series and literature review
50. Transfusion burden in early childhood plays an important role in iron overload in Diamond‐Blackfan anaemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.